| Pharmaceutical Information |
| Drug Name |
Delafloxacin |
| Drug ID |
BADD_D02494 |
| Description |
Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. |
| Indications and Usage |
Delafloxacin is indicated for the treatment of acute bacterial skin and skin structure infections caused by the Gram-positive organisms Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis as well as the Gram-negative organisms Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
J01MA23 |
| DrugBank ID |
DB11943
|
| KEGG ID |
D09330
|
| MeSH ID |
C477891
|
| PubChem ID |
487101
|
| TTD Drug ID |
D0V9BU
|
| NDC Product Code |
Not Available |
| UNII |
6315412YVF
|
| Synonyms |
delafloxacin | 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 3-quinolinecarboxylic acid, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo- | ABT 492 | ABT492 | ABT-492 | RX-3341 | Baxdela |
|
| Chemical Information |
| Molecular Formula |
C18H12ClF3N4O4 |
| CAS Registry Number |
189279-58-1 |
| SMILES |
C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Arthralgia | 15.01.02.001 | 0.000330% | | | | Confusional state | 19.13.01.001; 17.02.03.005 | 0.000107% | | | | Diarrhoea | 07.02.01.001 | 0.001157% | | | | Dyspnoea | 02.11.05.003; 22.02.01.004 | 0.000165% | | | | Hypoaesthesia | 23.03.03.081; 17.02.06.023 | 0.000165% | | Not Available | | Insomnia | 19.02.01.002; 17.15.03.002 | 0.000165% | | | | Nausea | 07.01.07.001 | 0.000248% | | | | Neuropathy peripheral | 17.09.03.003 | 0.000049% | | Not Available | | Rash | 23.03.13.001 | 0.000437% | | Not Available | | Tendon pain | 15.07.01.009 | 0.000107% | | Not Available |
|
The 1th Page
1
Total 1 Pages
|
|
